Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02806414 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
A Phase 1 study of Rosacea, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02806414 is a Phase 1 study of Rosacea that has completed, run by University of California, San Diego. The registered enrollment target is 25 participants, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02806414, a Phase 1 study of Rosacea, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on the skin) in rosacea. This is a single-site 16-week open-label study at University of California, San Diego. The investigators will do this by first measuring serine protease activity and cathelicidin and skin microbiome of all subjects. All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks. Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping and/or skin swabs. At the end of the study, tape strips and skin swabs will be analyzed to determine serine protease activity and skin microbiome of participants at each of their visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at changes in serine protease activity and LL-37 expression and skin microbiome over time, and they will also determine whether or not these changes correlate with disease severity.
Conditions Studied
Interventions
- DRUG Ivermectin
Study Locations (1)
California
- UCSD Division of Dermatology - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02806414
The ClinicalTrials.gov registry entry for NCT02806414 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (90% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Ivermectin is the first listed.
NCT02806414 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02806414 about?
NCT02806414 is a clinical study titled "Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.". This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on the skin) in rosacea. This is a single-site 16-week open-label study at University of California, San Diego. The ...
What is the current status of trial NCT02806414?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-07. Estimated completion is 2021-05.
What conditions does trial NCT02806414 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02806414?
The interventions under investigation include: Ivermectin (DRUG).
Who is sponsoring clinical trial NCT02806414?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02806414 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.